Tandem Diabetes Care (NASDAQ:TNDM) Announces Earnings Results, Beats Estimates By $0.01 EPS

Key Points

• Improved quarterly performance: Tandem Diabetes Care reported a second-quarter loss of $0.31 per share, $0.01 better than estimates, while revenue rose 5.8% year over year to $254.6 million, narrowly missing expectations.
• Margins and growth momentum strengthened: Gross margin reached 57%, adjusted EBITDA margin remained at 3%, and worldwide pump shipments increased more than 10% to approximately 33,000. The company reaffirmed its 2026 revenue guidance of $1.065 billion-$1.085 billion.
• Product opportunity offset by operational risks: Tandem expects to launch its Mobi Tubeless insulin pump in the second half of 2026, pending FDA clearance, but infusion-set supply constraints and declining cash and investments remain concerns.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) posted its quarterly earnings data on Thursday. The medical device company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.01, FiscalAI reports. The business had revenue of $254.56 million during the quarter, compared to analysts' expectations of $254.99 million. Tandem Diabetes Care had a negative net margin of 9.20% and a negative return on equity of 53.88%. Tandem Diabetes Care's revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.78) earnings per share.

Here are the key takeaways from Tandem Diabetes Care's conference call:

• Second-quarter momentum improved: Worldwide pump shipments rose more than 10% year over year and sequentially to approximately 33,000, while sales increased 6% to $255 million. U.S. new starts were nearly flat year over year but improved more than 20% sequentially, with MDI conversions growing mid-single digits.
• The PayGo pharmacy strategy gained early traction, with pharmacy representing approximately 10% of U.S. pump shipments and sales in its first full quarter. Formulary coverage reached about 45%, and management said pharmacy supply pricing was above its initial $350-per-month modeling assumption, although adoption of supplies is lagging pump adoption.
• Profitability continued to improve, with gross margin reaching 57%, up five percentage points year over year, and adjusted EBITDA margin reaching 3% for the fourth consecutive quarter. The company reaffirmed 2026 sales guidance of $1.065 billion-$1.085 billion, gross margin guidance of 56%-57%, and adjusted EBITDA margin guidance of 5%-6%.
• Tandem submitted Mobi Tubeless to the FDA in the second quarter and expects a scaled launch in the second half of 2026, subject to clearance. Management views the product’s tubeless, extended-wear capability as a potential growth and margin catalyst, particularly in 2027.
• Infusion-set supply constraints weighed on U.S. and international results, with the company citing the greatest impact in the second quarter and expecting residual effects through the next several quarters. Cash and investments declined to $456 million from $570 million in the prior quarter, partly due to CRM spending, a Roche settlement payment, and an additional CeQur investment.

Tandem Diabetes Care Price Performance

Shares of NASDAQ TNDM traded up $3.59 during mid-day trading on Friday, hitting $22.38. 5,434,655 shares of the stock traded hands, compared to its average volume of 2,170,484. The company has a market cap of $1.53 billion, a PE ratio of -15.99 and a beta of 1.54. Tandem Diabetes Care has a twelve month low of $10.00 and a twelve month high of $29.65. The company has a debt-to-equity ratio of 4.54, a current ratio of 3.58 and a quick ratio of 3.07. The firm has a 50 day simple moving average of $16.87 and a two-hundred day simple moving average of $18.86.

Tandem Diabetes Care News Summary

Here are the key news stories impacting Tandem Diabetes Care this week:

• Positive Sentiment: Improved quarterly profitability: Tandem reported a second-quarter 2026 loss of $0.31 per share, slightly better than analyst estimates for a loss of $0.32-$0.34 and substantially improved from a $0.48-$0.78 loss in the year-ago period. Revenue rose 5.8% year over year to $254.6 million, broadly in line with expectations. Tandem Diabetes Care Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Strong gross-margin expansion: Second-quarter gross margin increased to 57%, up 460 basis points from a year earlier. The improvement supports the market’s view that Tandem’s cost structure and operating leverage are moving in the right direction. Tandem Diabetes Care Announces Second Quarter 2026 Financial Results
• Positive Sentiment: Analyst remains bullish: TD Cowen analyst Mathew Blackman reiterated a Buy rating and a $28 price target, citing building momentum ahead of Tandem’s Mobi tubeless launch and continued margin improvement. Analyst Reiterates Buy on Tandem
• Neutral Sentiment: Full-year outlook is largely unchanged: Tandem’s fiscal 2026 revenue guidance of approximately $1.1 billion-$1.1 billion is in line with consensus, providing stability but not a major upward surprise. Tandem Diabetes Care Earnings Report
• Negative Sentiment: Revenue narrowly missed some estimates: Quarterly sales of $254.6 million were just below the roughly $255.0 million consensus forecast, and Tandem remains unprofitable, which could limit the stock’s upside if product launches or growth do not accelerate. Tandem Diabetes Care Reports Q2 Loss

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on TNDM. Benchmark assumed coverage on shares of Tandem Diabetes Care in a report on Monday, May 11th. They set a "hold" rating for the company. Barclays set a $55.00 price objective on Tandem Diabetes Care and gave the stock an "overweight" rating in a research report on Monday, May 11th. Mizuho decreased their target price on Tandem Diabetes Care from $24.00 to $20.00 and set a "neutral" rating on the stock in a research report on Wednesday, July 15th. The Goldman Sachs Group set a $21.00 target price on Tandem Diabetes Care in a research note on Wednesday, May 27th. Finally, Truist Financial reissued a "buy" rating and issued a $31.00 target price (down from $35.00) on shares of Tandem Diabetes Care in a report on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $28.98.

Institutional Trading of Tandem Diabetes Care

A number of hedge funds have recently made changes to their positions in TNDM. Caitong International Asset Management Co. Ltd increased its stake in shares of Tandem Diabetes Care by 200.0% in the third quarter. Caitong International Asset Management Co. Ltd now owns 2,205 shares of the medical device company's stock valued at $27,000 after buying an additional 1,470 shares during the period. Smartleaf Asset Management LLC boosted its position in Tandem Diabetes Care by 80.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,330 shares of the medical device company's stock worth $30,000 after buying an additional 593 shares during the period. Quarry LP grew its holdings in Tandem Diabetes Care by 2,597.1% during the 3rd quarter. Quarry LP now owns 3,695 shares of the medical device company's stock worth $45,000 after acquiring an additional 3,558 shares during the last quarter. Van ECK Associates Corp grew its holdings in Tandem Diabetes Care by 67.4% during the 4th quarter. Van ECK Associates Corp now owns 3,430 shares of the medical device company's stock worth $75,000 after acquiring an additional 1,381 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in Tandem Diabetes Care by 218.6% in the 2nd quarter. Tower Research Capital LLC TRC now owns 9,168 shares of the medical device company's stock valued at $171,000 after acquiring an additional 6,290 shares during the period.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc NASDAQ: TNDM, headquartered in San Diego, California, is a medical device company focused on the design, development and commercialization of innovative insulin delivery systems for people with insulin-dependent diabetes. Founded in 2006, the company introduced its first product, the t:slim® Insulin Pump, in 2011 and has since built a portfolio of next-generation pumps featuring touchscreen interfaces, remote software updates and integrated continuous glucose monitoring (CGM) capabilities.

The company's flagship offering, the t:slim X2® Insulin Pump, is engineered to work with leading CGM sensors and features automated insulin delivery algorithms that adjust basal insulin rates based on real-time glucose trends.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source